Next Article in Journal / Special Issue
Multiple Vaccinations and the Enigma of Vaccine Injury
Previous Article in Journal
The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study
Previous Article in Special Issue
Missed Opportunities of Flu Vaccination in Italian Target Categories: Insights from the Online EPICOVID 19 Survey
Article

Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes

1
Unit of Clinical Governance, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia,42122 Reggio Emilia, Italy
2
Department of Public Health, Azienda Unità Sanitaria Locale—IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(4), 675; https://doi.org/10.3390/vaccines8040675
Received: 16 October 2020 / Revised: 9 November 2020 / Accepted: 11 November 2020 / Published: 12 November 2020
We explored whether influenza vaccination (IV) affects susceptibility to SARS-CoV-2 infection and clinical outcomes in COVID-19 patients in 17,608 residents of the Italian province of Reggio Emilia undergoing a SARS-CoV-2 test. Exposure to IV was ascertained and the strength of the association with SARS-CoV-2 positivity expressed with odds ratios (OR). Rates of hospitalisations and death in those found positive were assessed and hazard ratios (HR) were estimated. The prevalence of IV was 34.3% in the 4885 SARS-CoV-2 positive and 29.5% in the 12,723 negative subjects, but the adjusted OR indicated that vaccinated individuals had a lower probability of testing positive (OR = 0.89; 95% CI 0.80–0.99). Among the 4885 positive individuals, 1676 had received IV. After adjusting for confounding factors, there was no association between IV and hospitalisation (1.00; 95% CI 0.84–1.29) or death (HR = 1.14; 95% CI 0.95–1.37). However, for patients age ≥65 vaccinated close to the SARS-CoV-2 outbreak, HRs were 0.66 (95% CI: 0.44–0.98) and 0.70 (95% CI 0.50–1.00), for hospitalisation and death, respectively. In this study, IV was associated with a lower probability of COVID-19 diagnosis. In COVID-19 patients, overall, IV did not affect outcomes, although a protective effect was observed for the elderly receiving IV almost in parallel with the SARS-CoV-2 outbreak. These findings provide reassurance in planning IV campaigns and underscore the need for exploring further their impact on COVID-19. View Full-Text
Keywords: influenza vaccine; SARS-Cov-2; COVID-19; case-negative study; retrospective cohort study influenza vaccine; SARS-Cov-2; COVID-19; case-negative study; retrospective cohort study
MDPI and ACS Style

Ragni, P.; Marino, M.; Formisano, D.; Bisaccia, E.; Scaltriti, S.; Bedeschi, E.; Grilli, R. Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes. Vaccines 2020, 8, 675. https://doi.org/10.3390/vaccines8040675

AMA Style

Ragni P, Marino M, Formisano D, Bisaccia E, Scaltriti S, Bedeschi E, Grilli R. Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes. Vaccines. 2020; 8(4):675. https://doi.org/10.3390/vaccines8040675

Chicago/Turabian Style

Ragni, Pietro, Massimiliano Marino, Debora Formisano, Eufemia Bisaccia, Stefania Scaltriti, Emanuela Bedeschi, and Roberto Grilli. 2020. "Association between Exposure to Influenza Vaccination and COVID-19 Diagnosis and Outcomes" Vaccines 8, no. 4: 675. https://doi.org/10.3390/vaccines8040675

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop